VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

SABCS 2022 | ALICE: atezolizumab + immunogenic chemotherapy in metastatic TNBC

Jon Amund Kyte, MD, PhD, University of Oslo, Oslo, Norway provides an overview of the Phase IIb ALICE (NCT03164993) trial investigating atezolizumab in combination with immunogenic chemotherapy in metastatic triple-negative breast cancer (TNBC), exploring whether the efficacy of immune checkpoint inhibitors can be enhanced via the addition of selective chemotherapy. Additionally, the trial set to examine whether a response is possible in patients who are PD-L1-negative. The PD-L1 inhibitor atezolizumab was investigated in combination with doxorubicin, which has been reported to provoke immunogenic cell death, and low-dose metronomic cyclophosphamide, which has been reported to counter immunosuppressive cells. The primary efficacy endpoint was progression-free survival (PFS) and safety was a co-primary endpoint. Secondary endpoints include objective response rate (ORR), clinical benefit rate (CBR), durable response rate (DRR), overall survival (OS) and biomarkers. A significantly improved PFS was observed in patients receiving atezolizumab in combination with versus chemotherapy alone. The progression-free proportion after 15 months was 14.7% with atezolizumab plus chemotherapy versus 0% with chemotherapy alone. Additionally, A benefit was indicated in patients with PD-L1 negative disease, and the combination was well tolerated. The results are published in Nature Medicine: https://www.nature.com/articles/s41591-022-02126-1. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter